Analyst Price Target is $19.50
▲ +466.86% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Surrozen in the last 3 months. The average price target is $19.50, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 466.86% upside from the last price of $3.44.
Current Consensus is
The current consensus among 3 contributing investment analysts is to buy stock in Surrozen.
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.